Overview

Tagrisso is a medicine for treating a lung cancer called non-small cell lung cancer (NSCLC).

It is used on its own in patients whose cancer cells have certain mutations (changes) in a gene for a
protein called EGFR.

• In patients whose cancer cells have genetic changes known as Ex19del or L858R and whose
cancer has not spread to other organs and has been completely removed by surgery, the
medicine is given to help prevent the cancer from coming back (adjuvant therapy).

• In patients whose cancer cells have mutations known as ‘activating mutations’ and whose
cancer is advanced or has spread, Tagrisso is given as the first treatment.

• In patients whose cancer cells have T790M mutations and whose cancer is advanced or has
spread, the medicine may be given after other treatments.

Tagrisso contains the active substance osimertinib.

Tagrisso can only be obtained with a prescription and treatment should be started and supervised by a
doctor who is experienced in the use of cancer medicines. Before starting treatment, the doctor should
use a genetic test to confirm that the patient has an EGFR mutation.

Tagrisso is available as 40 and 80 mg tablets. The patient should take 80 mg once a day for as long as
the disease improves or remains stable, or does not come back after surgery, and the side effects are
tolerable. If certain side effects develop, the doctor may decide to reduce the dose or stop treatment.

For more information about using Tagrisso, see the package leaflet or contact your doctor or
pharmacist.

The active substance in Tagrisso, osimertinib, is a type of cancer medicine called a tyrosine kinase inhibitor. It blocks the activity of EGFR, which normally controls growth and division of cells. In lung cancer cells, EGFR is often overactive, causing uncontrolled growth of cancer cells. By blocking EGFR, osimertinib helps to reduce the growth and spread of the cancer.

Four studies have found Tagrisso to be effective at shrinking tumours in patients with NSCLC and at
slowing down the worsening of the cancer. Another study found it was effective at helping to prevent
the cancer from coming back in patients who had surgery to completely remove the cancer.

In two studies involving 411 previously treated patients who had T790M mutations, the overall
response rates (the proportion of patients whose tumours shrank) with Tagrisso was 66% and the
response lasted an average of 12.5 months. In these studies, Tagrisso was not compared with any
other treatment.

A third study in 419 previously treated patients with T790M mutations looked mainly at how effective
Tagrisso was at preventing the cancer from worsening, comparing it with a platinum-based
chemotherapy (the standard treatment for NSCLC). In patients taking Tagrisso, the cancer did not get
worse for around 10.1 months compared with 4.4 months in patients on chemotherapy.

In a fourth study of 556 patients with activating mutations, patients taking Tagrisso as a first
treatment lived for 18.9 months without their disease getting worse compared with 10.2 months in
patients receiving treatment with other medicines (either erlotinib or gefitinib).

Finally, in a study involving 682 patients with Ex19del or L858R mutations who had surgery to
completely remove the cancer, 89% (302 out of 339) of patients taking Tagrisso were still alive and
disease-free after at least 1 year of treatment compared with 54% (184 out of 343) of patients taking
a placebo.

The most common side effects with Tagrisso (which may affect more than 1 in 10 people) are
diarrhoea, rash, paronychia (nail bed infection), dry skin, stomatitis (inflammation of the lining of the
mouth), decreased appetite, itching, and a decrease in the levels of white blood cells and platelets.

Tagrisso must not be used together with St. John’s wort (a herbal preparation used to treat
depression).

For the full list of restrictions and side effects with Tagrisso, see the package leaflet.

Patients whose cancer cells have EGFR mutations have a poor prognosis and limited treatment options;
therefore, there is a high unmet medical need. Tagrisso has been shown in studies to be effective at
shrinking tumours in patients with these mutations and at slowing down the worsening of the cancer.
The medicine is also effective at preventing the cancer from coming back in patients with EGFR
mutations who have had surgery to completely remove the cancer. Regarding safety, the adverse
effects with Tagrisso are similar to other medicines of the same class and are considered acceptable.

The European Medicines Agency therefore concluded that Tagrisso’s benefits are greater than its risks
and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe
and effective use of Tagrisso have been included in the summary of product characteristics and the
package leaflet.

As for all medicines, data on the use of Tagrisso are continuously monitored. Suspected side effects
reported with Tagrisso are carefully evaluated and any necessary action taken to protect patients.

Tagrisso received a conditional marketing authorisation valid throughout the EU on on 2 February 2016. This was switched to a full marketing authorisation on 24 April 2017.

Tagrisso : EPAR - Medicine overview

български (BG) (104.09 KB - PDF)
español (ES) (75.91 KB - PDF)
čeština (CS) (101.23 KB - PDF)
dansk (DA) (75.23 KB - PDF)
Deutsch (DE) (76.76 KB - PDF)
eesti keel (ET) (73.74 KB - PDF)
ελληνικά (EL) (110.55 KB - PDF)
français (FR) (76.93 KB - PDF)
hrvatski (HR) (96.39 KB - PDF)
italiano (IT) (75.46 KB - PDF)
latviešu valoda (LV) (98.2 KB - PDF)
lietuvių kalba (LT) (99.19 KB - PDF)
magyar (HU) (97.47 KB - PDF)
Malti (MT) (102.05 KB - PDF)
Nederlands (NL) (75.17 KB - PDF)
polski (PL) (100.74 KB - PDF)
português (PT) (75.64 KB - PDF)
română (RO) (98.36 KB - PDF)
slovenčina (SK) (100.49 KB - PDF)
slovenščina (SL) (95.05 KB - PDF)
Suomi (FI) (75.27 KB - PDF)
svenska (SV) (75.64 KB - PDF)

Tagrisso : EPAR - Risk-management-plan summary

Product information

Tagrisso : EPAR - Product Information

български (BG) (950.3 KB - PDF)
español (ES) (1.51 MB - PDF)
čeština (CS) (1.03 MB - PDF)
dansk (DA) (1.32 MB - PDF)
Deutsch (DE) (1.33 MB - PDF)
eesti keel (ET) (1.29 MB - PDF)
ελληνικά (EL) (980.94 KB - PDF)
français (FR) (973 KB - PDF)
hrvatski (HR) (1.61 MB - PDF)
íslenska (IS) (1.17 MB - PDF)
italiano (IT) (932.9 KB - PDF)
latviešu valoda (LV) (1.62 MB - PDF)
lietuvių kalba (LT) (1.4 MB - PDF)
magyar (HU) (1.26 MB - PDF)
Malti (MT) (1.47 MB - PDF)
Nederlands (NL) (2.26 MB - PDF)
norsk (NO) (1.33 MB - PDF)
polski (PL) (1.6 MB - PDF)
português (PT) (982.13 KB - PDF)
română (RO) (1.08 MB - PDF)
slovenčina (SK) (992.01 KB - PDF)
slovenščina (SL) (1.65 MB - PDF)
Suomi (FI) (1.28 MB - PDF)
svenska (SV) (1.46 MB - PDF)

Latest procedure affecting product information: II/0052

28/09/2023

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Tagrisso : EPAR - All Authorised presentations

български (BG) (40.25 KB - PDF)
español (ES) (52.44 KB - PDF)
čeština (CS) (29.51 KB - PDF)
dansk (DA) (28.75 KB - PDF)
Deutsch (DE) (30.25 KB - PDF)
eesti keel (ET) (45.31 KB - PDF)
ελληνικά (EL) (38.35 KB - PDF)
français (FR) (37 KB - PDF)
hrvatski (HR) (37.54 KB - PDF)
íslenska (IS) (27.69 KB - PDF)
italiano (IT) (29.75 KB - PDF)
latviešu valoda (LV) (28.71 KB - PDF)
lietuvių kalba (LT) (31.16 KB - PDF)
magyar (HU) (32.86 KB - PDF)
Malti (MT) (38.52 KB - PDF)
Nederlands (NL) (28.34 KB - PDF)
norsk (NO) (28.52 KB - PDF)
polski (PL) (45.82 KB - PDF)
português (PT) (29.7 KB - PDF)
română (RO) (31.4 KB - PDF)
slovenčina (SK) (31.67 KB - PDF)
slovenščina (SL) (31.42 KB - PDF)
Suomi (FI) (26.41 KB - PDF)
svenska (SV) (27.32 KB - PDF)

Product details

Name of medicine
Tagrisso
Active substance
osimertinib mesilate
International non-proprietary name (INN) or common name
osimertinib
Therapeutic area (MeSH)
Carcinoma, Non-Small-Cell Lung
Anatomical therapeutic chemical (ATC) code
L01XE

Pharmacotherapeutic group

  • Other antineoplastic agents
  • Protein kinase inhibitors

Therapeutic indication

TAGRISSO as monotherapy is indicated for:

- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations

- the first-line treatment of adult patients NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

TAGRISSO as monotherapy is indicated for:
- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

Authorisation details

EMA product number
EMEA/H/C/004124

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Marketing authorisation holder
AstraZeneca AB

SE-151 85 Södertälje
Sweden

Opinion adopted
17/12/2015
Marketing authorisation issued
01/02/2016
Revision
19

Assessment history

Tagrisso : EPAR - Procedural steps taken and scientific information after authorisation

Tagrisso-H-C-PSUSA-00010472-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - Annex IV

Tagrisso-H-C-004124-II-0039-G : EPAR - Assessment Report - Variation

CHMP post-authorisation summary of positive opinion for Tagrisso (II-39-G)

Tagrisso : EPAR - Scientific conclusions

Tagrisso : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - Annex IV

Tagrisso-H-C-4124-II-0019 : EPAR - Assessment Report - Variation

CHMP post-authorisation summary of positive opinion for Tagrisso II/0019

Tagrisso-H-C-4124-II-0009-G : EPAR - Assessment Report - Variation

Tagrisso : EPAR - Public assessment report

CHMP summary of opinion for Tagrisso

Topics

This page was last updated on

How useful do you find this page?